HYDRALAZINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Hydralazine Hydrochloride patents expire, and what generic alternatives are available?
Hydralazine Hydrochloride is a drug marketed by Abraxis Pharm, Adrastea Pharma, Am Regent, Eugia Pharma, Fresenius Kabi Usa, Hikma, Mylan Institutional, Navinta Llc, Rising, Smith And Nephew, Solopak, Teva Parenteral, Actavis Elizabeth, Actavis Grp Ptc, Alkem Labs Ltd, Anda Repository, Ascot, Cadila Pharms Ltd, Chartwell Rx, Glenmark Pharms Ltd, Halsey, Heritage Pharms, Heritage Pharms Inc, Hetero Labs Ltd Iii, Impax Labs, Invagen Pharms, Ivax Sub Teva Pharms, Mutual Pharm, Mylan, Pliva, Purepac Pharm, Quantum Pharmics, Sciegen Pharms Inc, Strides Pharma, Superpharm, Upsher Smith Labs, Usl Pharma, Vangard, Vitarine, Watson Labs, West Ward, Solvay, and Ivax Pharms. and is included in ninety-four NDAs.
The generic ingredient in HYDRALAZINE HYDROCHLORIDE is hydralazine hydrochloride; hydrochlorothiazide; reserpine. There are twenty-one drug master file entries for this compound. Additional details are available on the hydralazine hydrochloride; hydrochlorothiazide; reserpine profile page.
Summary for HYDRALAZINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 43 |
NDAs: | 94 |
Finished Product Suppliers / Packagers: | 40 |
Raw Ingredient (Bulk) Api Vendors: | 118 |
Clinical Trials: | 65 |
Patent Applications: | 1,199 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for HYDRALAZINE HYDROCHLORIDE |
DailyMed Link: | HYDRALAZINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for HYDRALAZINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Shahid Sadoughi University of Medical Sciences and Health Services | Phase 3 |
National Institute for Medical Research Development (NIMAD), Iran | Phase 3 |
McMaster University | Phase 3 |
Pharmacology for HYDRALAZINE HYDROCHLORIDE
Drug Class | Arteriolar Vasodilator |
Physiological Effect | Arteriolar Vasodilation |